Wall Street Zen Upgrades Structure Therapeutics Amid Analyst Activity

On November 28, 2023, Wall Street Zen upgraded Structure Therapeutics (NASDAQ: GPCR) from a “sell” rating to a “hold” rating. This change comes as a part of a broader reassessment of the company’s stock by various analysts in recent weeks.

Analysts have shown mixed sentiments towards Structure Therapeutics. While Wall Street Zen adjusted its position, HC Wainwright reaffirmed a “buy” rating and set a target price of $60.00. In a contrasting move, Morgan Stanley increased their price target for the company’s shares from $120.00 to $125.00 while maintaining an “overweight” rating.

Mixed Ratings from Analysts

On December 8, Stifel Nicolaus raised its price objective for Structure Therapeutics from $50.00 to $90.00 and issued a “buy” rating. In contrast, Zacks Research downgraded the stock from a “hold” rating to a “strong sell” on October 17. Notably, Lifesci Capital upgraded the shares to a “strong-buy” rating back on September 8.

Currently, of the analysts covering Structure Therapeutics, one has rated the stock as a strong buy, eleven have issued buy ratings, and two analysts have recommended a sell. According to data from MarketBeat, the average rating for the stock stands at “Moderate Buy,” with an average target price of $95.78.

Recent Earnings and Institutional Interest

Structure Therapeutics released its quarterly earnings on November 6, revealing a loss of ($0.37) earnings per share, which missed the consensus estimate by ($0.01). Analysts predict that the company will report an earnings per share of ($0.82) for the current fiscal year.

Institutional investors have shown increased interest in Structure Therapeutics. In the second quarter, the State of Wyoming acquired a new stake worth about $28,000. EverSource Wealth Advisors LLC significantly raised its position by 530.0%, now holding 1,071 shares valued at $30,000 after purchasing an additional 901 shares.

Additionally, the National Bank of Canada FI raised its stake by 1,448.2%, now owning 2,957 shares valued at $51,000. Other investors, such as Assetmark Inc. and PNC Financial Services Group Inc., have also increased their holdings in the company.

Currently, approximately 91.78% of Structure Therapeutics stock is owned by hedge funds and institutional investors, underscoring significant institutional confidence in the company.

Founded as a clinical-stage global biopharmaceutical entity, Structure Therapeutics focuses on developing novel oral therapeutics aimed at addressing chronic diseases with unmet medical needs. The company’s lead candidate is GSBR-1290, an oral small molecule agonist targeting the glucagon-like-peptide-1 receptor, which is important for treating type-2 diabetes mellitus and obesity.

As the landscape of biotech investment continues to evolve, the fluctuations in ratings and institutional interest in Structure Therapeutics reflect both the challenges and opportunities present in the biopharmaceutical sector.